CHIKV-VLP is under clinical development by Bavarian Nordic and currently in Pre-Registration for Chikungunya Fever. According to GlobalData, Pre-Registration drugs for Chikungunya Fever have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how CHIKV-VLP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CHIKV-VLP overview
CHIKV-VLP is under development for the prevention of chikungunya viral infection. The therapeutic candidate is administered through intramuscular route. The vaccine candidate is a virus like particle vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins.
Bavarian Nordic overview
Bavarian Nordic is a biotechnology company specializing in the research, development, and manufacturing of vaccines. The company’s primary activities include vaccine development, commercial-scale manufacturing, and commercial operations. Bavarian Nordic‘s product portfolio includes vaccines for diseases such as tick-borne encephalitis, smallpox, monkeypox, rabies, cholera, and typhoid. The major brands offered by the company include Encepur, Jynneos, Imvamune, Imvanex, Rabipur, RabAvert, Vaxchora, and Vivotif. The company operates its commercial-scale manufacturing facility in Kvistgaard, Denmark. It operates commercial, research, and development centers in Canada, Switzerland, Germany, Italy, Spain, and Sweden. Bavarian Nordic is headquartered in Hellerup, Denmark.
For a complete picture of CHIKV-VLP’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
